Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing
January 04 2024 - 6:00AM
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an
innovative life sciences technology company providing mission
critical automation solutions to facilitate the efficient
manufacturing and fast, safe release of healthcare products, today
announced that Samsung Biologics (KRX: 207940.KS) has selected the
Growth Direct® platform to automate its microbial quality control
processes to deliver increased efficiency, more robust data
integrity and scalable quality control operations.
“Samsung Biologics is a leading global contract development and
manufacturing organization (CDMO) and has demonstrated an
unwavering commitment to automation and quality management in
biopharmaceutical manufacturing,” said Robert Spignesi, President
and CEO of Rapid Micro Biosystems. “The Growth Direct® improves
operational efficiency and data integrity in the quality control
microbiology lab, and we are proud to partner with Samsung
Biologics.”
Global pharmaceutical manufacturers rely on the Growth Direct
platform to meet both today’s microbiological quality control
standards and tomorrow’s challenges. It is the only fully
automated, non-destructive growth-based platform for microbiology
quality control testing that offers faster time to results,
improved data integrity, and enhanced accuracy, with greater sample
capacity.
To learn more about the Company and the Growth Direct® platform
please visit: Rapid Micro Biosystems.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology
company providing mission critical automation solutions to
facilitate the efficient manufacturing and fast, safe release of
healthcare products such as biologics, vaccines, cell and gene
therapies, and sterile injectables. The Company’s flagship Growth
Direct system automates and modernizes the antiquated, manual
microbial quality control (“MQC”) testing workflows used in the
largest and most complex pharmaceutical manufacturing operations
across the globe. The Growth Direct system brings the quality
control lab to the manufacturing floor, unlocking the power of MQC
automation to deliver the faster results, greater accuracy,
increased operational efficiency, better compliance with data
integrity regulations, and quicker decision making that customers
rely on to ensure safe and consistent supply of important
healthcare products. The Company is headquartered and has U.S.
manufacturing in Lowell, Massachusetts, with global locations in
Lexington, Massachusetts, Switzerland, Germany, and the
Netherlands. For more information, please
visit www.rapidmicrobio.com or follow the Company on
Twitter at @rapidmicrobio or on LinkedIn.
About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a fully integrated,
end-to-end CDMO service provider, offering seamless development and
manufacturing solutions from cell line development to final aseptic
fill/finish as well as laboratory testing support for the
biopharmaceutical products we manufacture. Our state-of-the-art
facilities are cGMP compliant with bioreactors ranging from small
to large scales to serve varying client needs. To maximize our
operational efficiency and expand our capabilities in response to
growing biomanufacturing demand, Samsung Biologics recently
completed Bio Campus I with Plant 4 offering a combined 604KL total
capacity, and launched Bio Campus II with the construction of Plant
5, which will be operational in April 2025 adding 184KL
biomanufacturing capacity. Additionally, Samsung Biologics America
enables the company to work in closer proximity to clients based in
the U.S. and Europe. We continue to upgrade our capabilities to
accommodate our clients by investing in technologies such as an
antibody-drug conjugate (ADC) facility, a dedicated mRNA
manufacturing facility, and additional aseptic filling capacity. As
a sustainable CDMO partner of choice, we are committed to on-time,
in-full delivery of the products we manufacture with our flexible
manufacturing solutions, operational excellence, and proven
expertise.
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, but not limited to,
statements regarding the expected impact of the Growth Direct
system on Samsung Biologics' operational efficiency and data
integrity.
Forward-looking statements involve known and unknown risks,
uncertainties and assumptions which may cause actual results to
differ materially from any results expressed or implied by any
forward-looking statement, including the important factors outlined
under the caption “Risk Factors” in the Company's Annual Report on
Form 10-K filed with the Securities and Exchange Commission (“SEC”)
on March 10, 2023, as such factors may be updated from time to time
in its other filings with the SEC, which are available on the SEC's
website at www.sec.gov and the Investor Relations page of its
website at investors.rapidmicrobio.com. Although the Company
believes that the expectations reflected in its forward-looking
statements are reasonable, it cannot guarantee future results. The
Company has no obligation, and does not undertake any obligation,
to update or revise any forward-looking statement made in this
press release to reflect changes since the date of this press
release, except as may be required by law.
Rapid Micro Biosystems Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com
Rapid Micro Biosystems Media Contact:
media@rapidmicrobio.com
Samsung Biologics Media Contact
Claire Kim, Head of Marketing Communications
cair.kim@samsung.com
Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart
From May 2024 to Jun 2024
Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart
From Jun 2023 to Jun 2024